Autres langues Exelixis, Inc.

Actions

EXEL

US30161Q1040

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/07/2026			Après clôture 01:55:05
53,03 ^USD	-5,25%		54,72	+3,18%

07/07	EXELIXIS, INC. : RBC Capital Markets est neutre	ZM
02/07	Exelixis : un profil risque-rendement equilibre avant des catalyseurs cles, selon UBS	MT

Autres langues

23/07	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
22/07	Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says
02/07	Afternoon Meeting: Wall Street celebra la debilidad
02/07	Analyst recommendations: Adobe, AA, Nike, Exelixis…
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Value-Defensive Index
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Growth-Defensive Index
29/06	Exelixis, Inc.(NasdaqGS:EXEL) dropped from Russell 1000 Defensive Index
22/06	Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
22/06	Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
01/06	Wall Street comienza junio en tensión
01/06	Wall Street startet nervös in den Juni
01/06	Wall Street Starts June on Edge
30/05	Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026
27/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
21/05	Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
21/05	Exelixis, Inc. Announces Presentations of Cabometyx and Zanzalintinib At 2026 2026 Annual Meeting
20/05	Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing
19/05	Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial
19/05	Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
19/05	Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer
11/05	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May 2026